CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Secretaria da Saúde (São Paulo - Estado). Instituto Butantan (Institutional affiliation from the last research proposal) Birthplace: Brazil
I hold a degree in Pharmacy and Biochemistry from the University of São Paulo (USP) (2001), a Masters and a Ph.D. in Clinical Analysis (Microbiology) from the School of Pharmaceutical Sciences at USP (FCF-USP). I completed three postdoctoral fellowships: in Tumor Biochemistry at FCF-USP (2008-2012), in Cancer Therapies at the Spanish National Cancer Research Center (CNIO) in Madrid, Spain (2012), and in Cancer Immunotherapy at the Institute of Biomedical Sciences of USP (ICB-USP), working in the Departments of Parasitology (2014-2016) and Microbiology (2016-2018). I was a FAPESP Young Investigator (2016-2020), leading projects in immunology and tumor immunotherapy. Currently, I am a Researcher at the Vaccine Development Laboratory of the Butantan Institute and a Collaborating Researcher at ICB-USP. In academia, I am responsible for courses in two USP graduate programsInterunit Biotechnology (PPIB) and Microbiology at ICB-USPand I coordinate university extension courses at both the Butantan Institute and ICB-USP. I also serve as a full advisor in the PPIB-USP and Microbiology graduate programs at ICB-USP, as well as at the Higher School of the Butantan Institute (ESIB). My scientific work is interdisciplinary, with expertise in Microbiology Education, Basic and Clinical Microbiology, Immunology, Tumor Immunology, Cell Biology, and Microorganism Pathogenicity. My projects range from pathogen-host interactions in bacterial infectious diseases to the development of immunotherapies and vaccines for tumor treatment. I also stand out for implementing active learning methodologies in microbiology and related fields. Currently, I am the President of the Organizing Committee for the XXVI Annual Scientific Meeting of the Butantan Institute, focused on the One Health theme.Professional Links: ORCID ID: https://orcid.org/0000-0002-3024-8045. Researcher ID: H-4290-2012. Google Scholar https://scholar.google.com.br/citations?hl=pt-BRuser=arSc5-MAAAAJview_op=list_works. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
In the last twelve years, solid evidence showed that the enzyme Indoleamine 2,3 dioxygenase-1 (IDO) is an important mediator of immune tolerance. While the similarities between IDO regulatory mechanisms and the molecular signature associated with cervical cancer and other tumors induced by human papillomavirus (HPV), the active role of IDO in these tumors has not been studied. Here, we wi…
Non-muscle invasive bladder cancer (NMIBC) represents approximately 70 to 80% of all bladder cancer cases. Standard treatment involves transurethral resection of the tumor followed by cycles of intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). However, around 30% of patients either do not respond to treatment or experience recurrence, underscoring the urgent need for more ef…
Trained immunity, an emerging concept in immunology, suggests that cells of the innate immune system can be "trained" after exposure to specific stimuli. This phenomenon strengthens and reprograms immune cells, resulting in a more effective and long-lasting response to different subsequent infectious diseases. Understanding trained immune response has significant implications for the deve…
Bladder cancer is one of the top ten most common cancers in the world, accounting for 90% of all urothelial malignancies. Approximately 70% of bladder tumors are non-muscle invasive at diagnosis and are treated with transurethral resection followed by intravesical Bacillus Calmette-Guérin instillation (BCG). This bacterium is used in cancer adjuvant therapy to reduce recurrence and metast…
Human Papillomavirus (HPV) is the etiologic agent of a variety of diseases, such as benign epithelial lesions, genital warts, laryngeal papillomas, and other diseases that are difficult to manage. In recent years, the role of HPV in triggering different types of tumors has been highlighted. It is known that HPV is responsible for more than 99% of cervical tumors, most of the anal tumors a…
Faithful to its inherent aggressive, melanomas are remarkably resistant to all forms of cancer therapies. The combination of chemotherapy with biomolecules such as IL-2 and IFN-alpha does not appear to be an effective management. However, clinical trials are underway to evaluate new therapeutic strategies. In this context, melatonin (MLT) has been shown to be an excellent adjunct to conve…
| 1 / 1 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 4 / 3 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 8 / 7 | All research grants and scholarships |
| Associated processes | |